Eli Lilly's stock drops as it slashes the price of Zepbound: Time to buy the dip?

This is no reason to panic.

Eli Lilly Further Cements Itself As The King Of Weight Loss

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Barchart on MSN

As Eli Lilly cuts Zepbound prices, should you buy, sell, or hold LLY stock?

Eli Lilly and Company (LLY) is a global pharmaceutical leader focused on discovering, developing, and commercializing ...

Think Eli Lilly Is Expensive? This Metric Says Otherwise.

The pharmaceutical stock can still deliver.

Eli Lilly's Strategic Moves in the Weight-Loss Drug Arena

In a significant move to address supply constraints, Eli Lilly announced a $6 billion investment to construct a new manufacturing facility in Huntsville, Alabama. This site is slated to produce both ...
Forbes

How LLY Stock Delivered $47 Billion To Shareholders

In the last decade, Eli Lilly stock (NYSE: LLY) has returned $47 billion to its shareholders via dividends and buybacks. This shareholder-centric approach has delivered solid results in 2025, with the ...

Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term. On December 3, Guggenheim ...

Eli Lilly: Retatrutide Justifies Hype With Best Weight Loss Data Yet - I'm Sold

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

4LLY : Eli Lilly's Options Frenzy: What You Need to Know

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...